Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 2014

View Archived Issues

Toxin-specific MAbs show efficacy in hamster model of CDAD

Urothelial carcinogen resistance model developed in rats

Interferon alpha inhibitor shows promise for the treatment of HIV encephalitis

Daiichi Sankyo recaps events of fourth quarter of fiscal 2013

Neurotrope and Stanford University collaborate on bryologs

Russian and U.S. researchers design new antibodies for HCV infection

Ensemble Therapeutics presents novel IL-17R modulators

Novel azithromycin derivative identified for pulmonary inflammation

Sanofi divulges novel P2Y12 receptor antagonists for thrombotic disorders

RedHill Biopharma and IntelGenx report promising RHB-103 bioavailability data

Adamas Pharmaceuticals receives milestone payment from Forest Laboratories

FDA grants orphan drug status to retinitis pigmentosa treatment candidate

IBI-302 investigated for AMD in vitro and in vivo

NIH funding to support Cognition Therapeutics' work in Alzheimer's disease

Oral fenretinide studied in new phase I trial in cystic fibrosis

WILEX and UCB terminate oncology collaboration

Gedeon Richter to buy majority stake in marketing company Mediplus

Empagliflozin evaluated in patients with diabetes and hypertension in phase III trials

CHMP issues positive opinion for Envarsus in kidney and liver transplant patients

Janssen withdraws application for intravenously administered Simponi in E.U.

Lanthio Pharma receives Dutch government loan to develop novel therapy for lung fibrosis

Avipero and Fusion Antibodies collaborate to humanize integrin antibodies

Sanford-Burnham and Daiichi Sankyo collaborate in cardiovascular-metabolic diseases

Neurotez and GCA Therapeutics sign Chinese license agreement for leptin derivatives

FDA extends Zerenex PDUFA goal date

Nuvilex initiates preclinical studies targeting pancreatic cancer pain and ascites

Empagliflozin approved in E.U.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...